Marina Biotech this week said that the US Patent and Trademark Office has issued a notice of allowance for three of the company's patent applications related to its delivery technologies.

The European Patent Office has also said it will grant the company a patent on a related technology, Marina said.

According to the company, the USPTO patent applications relate to the Smarticle amphoteric-based liposomal delivery vehicles Marina acquired from Novosom in 2010. The EPO application covers its DiLA2 amino acid-based liposomal delivery system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.